OBJECTIVES AND ACTIVITIES
Today we command the Research and Development spawning facilities offered by our State of Art drug formulations, chemical research and analytical development center; equipped with the latest equipments needed for combinational synthesis, ultramodern HPLC & GC systems etc.
- Development of NDDS
- Development of non infringing process
- Development of different Nitazoxanide dosage forms
- New process development for cost effectiveness
- Trouble shooting in plant
- Performance batches
- NCMR handling
- Bioequivalence and bioavailability as per DCI and International guidelines
- Drug regulatory affair and documentation: Dossiers for ANDA’s of different countries, NDA’ s filing in India, patents filing after a thorough scrutiny by attorneys, documentation for getting USFDA, documentation for R & D products, documentation for commercial samples, documentation for bioequivalence samples
- Contract research: from conceptualization till the final dossier of the product
|
Global Launch Status (with regard to the originator) |
Product |
Status |
Clarithromycin dispersible tablets |
First |
Fexofenadine dispersible tablets/ mouth dissolving NDDS |
First |
Roxithromycin taste masked granules |
First |
Roxithromycin dispersible tablets |
First |
Clarithromycin taste masked granules |
Second |
Clarithromycin sustained release tablets |
Second |
Nitazoxanide dispersible tablets/ dry syrup |
Second |
|
ACHIEVEMENTS
- Our R&D centre is recognised by the Government of India's Ministry of Science & Technology.
- Taste masking (Coated granulation) technology in macrolides, especially in Clarithromycin, Azithromycin and Roxithromycin.
- A grant of US patent for Development of non infringing process for Clarithromycin dispersible tablets and Clarithromycin- Once a day, a controlled release formulation completely developed in-house at its R&D centre.
- Developing of different Nitazoxanide dosage forms.
- Development of Fexofenadine (latest antiallergic) dispersible tablets and ready to file patent for the same.
- Sustained release form of Isoxsuprine HCl.
- Mouth dissolving tablet of Betamethasone.
- Development of tablet in tablet technology.
- 3 patents for API s for non infringing processes filed.
- A new separate wing in Herbal extract.
|
NDDS products developed by the company |
Product |
Therapeutic segment |
Clarie DT (Dispersible Tablet) |
Macrolide |
Clarie OD |
Macrolide |
Clarie SR (Sustained Release) |
Macrolide |
Excef DT (Dispersible Tablet) |
Antibiotic |
Suprox SR (Sustained Release) |
Vasodilator |
Fexidine Kid Tab (Dispersible Tablet) |
Anti histamine |
Netazox DT (Dispersible Tablet) |
Anti diarrhoea |
Agile SR Tab (Sustained Release) |
Anti inflammatory |
Askil tablet ( mouth dissolving) |
Anti inflammatory |
Roxy Kid Tab |
Macrolide |
Montelukast chewable tablet |
Anti asthmatic |
Metformin SR (Sustained Release) |
Anti diabetic |
Acamprostate enteric coated |
Anti alcoholic |
|
INFRASTRUCTURE
-
Manpower-100 scientists including 25 PhD’s.
-
Chemical Research Labs (4).
-
Analytical research Lab (instru) (3).
-
A small kilo lab (1)
-
Wet analysis Lab (1)
-
Stability studies lab (1)
-
Special Equipment Lab (1)
-
Office for regulatory department
-
Office of the IPR cell
-
Office for purchase and administration
-
Library
- Conference room
|
|
|
